Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 114

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 114
---
 statements.

5

KEROS THERAPEUTICS, INC. 

Condensed Consolidated Statements of Operations 

(In thousands, except share and per share data) 

(Unaudited)

THREE MONTHS ENDED MARCH 31,20252024REVENUE:Service and other revenue$15,891 $83 License revenue195,355 — Total revenue211,246 83 OPERATING EXPENSES:Research and development(48,709)(38,258)General and administrative(10,497)(10,308)Total operating expenses(59,206)(48,566)INCOME (LOSS) FROM OPERATIONS152,040 (48,483)OTHER INCOME (EXPENSE), NETDividend income6,792 5,806 Other expense, net(338)(437)Total other income, net6,454 5,369 Income (loss) before income taxes158,494 (43,114)Income tax provision(10,043)— Net income (loss)$148,451 $(43,114)Net income (loss) attributable to common stockholders — basic and diluted (Note 8)$148,451 $(43,114)Weighted-average shares of common stock outstanding — basic40,559,35535,685,422Weighted-average shares of common stock outstanding — diluted41,021,32535,685,422Net income (loss) per share of common stock — basic$3.66 $(1.21)Net income (loss) per share of common stock — diluted$3.62 $(1.21)

See notes to condensed consolidated financial statements. 

6

KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share data) 

(Unaudited)

COMMON STOCK$0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITY SHARESAMOUNTAs of December 31, 202440,554,705 $4 $1,140,328 $(568,779)$571,553 Exercise of common stock options7,342 — 4 — 4 Stock-based compensation— — 8,863 — 8,863 Net income (loss)— — — 148,451 148,451 As of March 31, 202